CCX168
Phase 2Small molecule
AmgenCCX168 is one of 45 small molecule programs targeting ANCA-Associated Vasculitis. It is currently in Phase 2.
2
Indications
9
Total Trials
0
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
99 competitors in Iga Nephropathy
#DrugCompanyPhaseTrials
1Avapro
SanofiPhase 3
Kerendia
BayerPhase 3
Farxiga
AstraZenecaPhase 3
Filspari
TTravere Therapeutics, Inc.
Phase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
LNP023
NovartisPhase 3
Medrol
PfizerPhase 2
Vanrafia
NovartisPhase 2
Telitacicept
VVor Biopharma
Phase 3
Mezagitamab
TakedaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
ANCA-Associated Vasculitis2 trials
IgA Nephropathy1 trial
Absorption1 trial
3 more indications
Cardiac1 trial
Interaction1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CCX168. EMBL-EBI & Wellcome Sanger Institute.
- [4]